
Full profile: /officials/T000476
Source: Congress.gov · FEC
Members who have signed on to support this bill since introduction. Source: Congress.gov.
The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →
The EPIC Act of 2025 addresses health policy matters and has been sent to the Senate Finance Committee for review. Without access to the bill's specific provisions, the legislation likely aims to modify how health programs or services are funded, regulated, or delivered, potentially affecting patients, healthcare providers, or insurance companies. The bill is still in early stages of the legislative process.
AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.
Verbatim text published on Congress.gov via GovInfo. Use Cmd+F / Ctrl+F to search within this excerpt.
[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [S. 832 Introduced in Senate (IS)] <DOC> 119th CONGRESS 1st Session S. 832 To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. _______________________________________________________________________ IN THE SENATE OF THE UNITED STATES March 4, 2025 Mr. Tillis (for himself, Mr. Budd, Mrs. Blackburn, Mr. Daines, and Mr. Lankford) introduced the following bill; which was read twice and referred to the Committee on Finance _______________________________________________________________________ A BILL To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Ensuring Pathways to Innovative Cures Act of 2025'' or the ``EPIC Act of 2025''. SEC. 2. EQUALIZING THE NEGOTIATION PERIOD BETWEEN SMALL-MOLECULE AND BIOLOGIC CANDIDATES UNDER THE DRUG PRICE NEGOTIATION PROGRAM. Section 1192(e)(1)(A)(ii) of the Social Security Act (42 U.S.C. 1320f-1(e)(1)(A)(ii)) is amended-- (1) by striking ``year, at least 7'' and inserting ``year-- ``(I) for initial price applicability years 2026 and 2027, at least 7''; and (2) by adding at the end the following: ``(II) for initial price applicability year 2028 and each subsequent initial price applicability year, at least 11 years will have elapsed since the date of such approval; and''. <all>
Bills by the same sponsor or covering overlapping subjects.